Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Graphite Bio, Inc. GRPH
$3.06
-$0.03 (-0.97%)
На 18:04, 12 мая 2023
+30.72%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
181647648.00000000
-
week52high
4.48
-
week52low
1.59
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-1.84000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 04:00
Описание компании
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Equal-Weight | 15 июл 2022 г. |
| BMO Capital | Outperform | 17 июн 2022 г. | |
| SVB Leerink | Outperform | Outperform | 13 мая 2022 г. |
| BTIG | Buy | 14 апр 2022 г. | |
| SVB Leerink | Outperform | Outperform | 22 мар 2022 г. |
| Cantor Fitzgerald | Overweight | 15 сент 2022 г. | |
| SVB Leerink | Market Perform | Outperform | 06 янв 2023 г. |
| RBC Capital | Sector Perform | Sector Perform | 06 янв 2023 г. |
| BMO Capital | Market Perform | Outperform | 06 янв 2023 г. |
| B of A Securities | Neutral | Buy | 18 янв 2023 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 03 февр 2023 г. |
| BTIG | Neutral | Buy | 25 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Porteus Matthew | A | 20000 | 20000 | 21 июн 2022 г. |
| Viney Joanne L. | A | 20000 | 20000 | 21 июн 2022 г. |
| JIMENEZ JOSEPH | A | 20000 | 20000 | 21 июн 2022 г. |
| KARSEN PERRY A | A | 20000 | 20000 | 21 июн 2022 г. |
| Jerel Davis | A | 20000 | 20000 | 21 июн 2022 г. |
| Hege Kristen | A | 20000 | 20000 | 21 июн 2022 г. |
| Shah Smital | A | 20000 | 20000 | 21 июн 2022 г. |
| Bassan Abraham | A | 20000 | 20000 | 21 июн 2022 г. |
| Carlo Rizzuto | A | 20000 | 20000 | 21 июн 2022 г. |
| Samsara BioCapital, L.P. | A | 8459314 | 350000 | 12 апр 2022 г. |
Новостная лента
Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround
Zacks Investment Research
10 янв 2023 г. в 11:17
Graphite Bio, Inc. (GRPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
Benzinga
10 янв 2023 г. в 07:33
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Graphite Bio: Underfollowed Gene Editing Play At An Attractive Valuation
Seeking Alpha
09 дек 2022 г. в 21:19
Graphite Bio has lost roughly 60% of its value over the past twelve months and is trading with a negative enterprise value despite its prospects in gene therapy. I discuss why I believe GRPH is a prime candidate for the Compounding Healthcare “Bio Boom” Portfolio.
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Investors Business Daily
20 окт 2022 г. в 10:14
Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock
Benzinga
17 июн 2022 г. в 14:37
BMO Capital Markets initiated coverage on Graphite Bio Inc (NASDAQ: GRPH), with a price target of $12 and an Outperform rating. The analyst notes that Graphite's gene editing approach involves a DNA repair mechanism that is known to be less vulnerable to errors.